FDA approves DNA testing company 23andMe's hereditary CRC test — 4 insights

The FDA awarded DNA testing company 23andMe clearance to include risk reports associated with hereditary colorectal cancer in its testing suite.

What you should know:

1. 23andMe will soon include information on genetic variants that can influence MUTYH-associated polyposis in its reports.

2. If customers opt-in to the report, 23andMe is providing an education module to help them interpret the results and understand the limitations of the report.

3. Hereditary CRC cases account for about 5 percent of all CRC cases, the company said.

4. Company CEO Anne Wojcicki said, "We are committed to giving people affordable and direct access to important health information that can impact their lives. We believe improved access to genetic testing and health information will help people engage in their own health."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast